製品番号: HY-16721

Cyclopropavir

(別名: Filociclovir; ZSM-I-62; MBX-400)

カスタマーレビュー

Based on 1 Customer Validation

Cyclopropavir (Filociclovir) is an orally active and broad-spectrum anti-herpesvirus compound. Cyclopropavir inhibits UL97 kinase activity. Cyclopropavir has antiviral activity against HCMV, MCMV, and HAdV6 viruses.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 98.0%
CAS 番号: 632325-71-4
分子式: C₁₁H₁₃N₅O₃
分子量:263.26

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Cyclopropavir 構造式

CAS 番号: 632325-71-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
溶剤 & 溶解度
- 体外
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
BSC-1	EC₅₀	>100 μM Compound: 2b	Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by ELISA Antiviral activity against Herpes simplex virus type 1 in african green monkey BSC1 cells by ELISA	[PMID: 19410465]
CCRF-HSB-2	CC₅₀	>20 μM Compound: CPV	Cytotoxicity against human HSB2 cells after 7 days by Cell-Titer Glo assay Cytotoxicity against human HSB2 cells after 7 days by Cell-Titer Glo assay	[PMID: 22607883]
Daudi	CC₅₀	>190 μM Compound: 6b	In vitro cytotoxic concentration required to inhibit Epstein-Barr virus (EBV) replication in Daudi cells In vitro cytotoxic concentration required to inhibit Epstein-Barr virus (EBV) replication in Daudi cells	[PMID: 14736238]
Daudi	EC₅₀	119 μM Compound: 6b	In vitro effective concentration required to inhibit Epstein-Barr virus (EBV) replication in Daudi cells In vitro effective concentration required to inhibit Epstein-Barr virus (EBV) replication in Daudi cells	[PMID: 14736238]
Fibroblast	EC₅₀	0.46 μM Compound: 3b	Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay Antiviral activity against Human cytomegalovirus Towne infected in human foreskin fibroblast cells by plaque reduction assay	[PMID: 19397271]
HepG2	CC₅₀	>50 μM Compound: 6b	In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line	[PMID: 14736238]
HFF	CC₅₀	>100 μM Compound: 2b	Cytotoxicity against HFF by visual cytotoxicity assay Cytotoxicity against HFF by visual cytotoxicity assay	[PMID: 19410465]
HFF	CC₅₀	>100 μM Compound: 3b	Cytotoxicity against HFF cells by neutral red uptake assay Cytotoxicity against HFF cells by neutral red uptake assay	[PMID: 19397271]
HFF	CC₅₀	>100 μM Compound: 3b	Cytotoxicity against HFF cells by plaque reduction assay Cytotoxicity against HFF cells by plaque reduction assay	[PMID: 19397271]
HFF	CC₅₀	>100 μM Compound: 6b	In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line In vitro cytotoxic concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line	[PMID: 14736238]
HFF	CC₅₀	>300 μM Compound: CPV	Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining Cytotoxicity against human HFF cells after 3 to 8 days by crystal voilet staining	[PMID: 22607883]
HFF	CC₅₀	>380 μM Compound: 1a	Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake) Cytotoxic concentration against AD169 strain of human cytomegalovirus infected HFF cells of human (by neutral red uptake)	[PMID: 15634003]
HFF	CC₅₀	>380 μM Compound: 2b	Cytotoxicity against HFF by neutral red uptake assay Cytotoxicity against HFF by neutral red uptake assay	[PMID: 19410465]
HFF	CC₅₀	>380 μM Compound: 6b	In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line In vitro cytotoxic concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line	[PMID: 14736238]
HFF	EC₅₀	>357 μM Compound: 6b	In vitro effective concentration required to inhibit varicella zoster virus (VZV) replication in HFF cell line In vitro effective concentration required to inhibit varicella zoster virus (VZV) replication in HFF cell line	[PMID: 14736238]
HFF	EC₅₀	120 μM Compound: 6b	In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line In vitro effective concentration required to inhibit AD169 strain of human cytomegalovirus (HCMV) replication in HFF cell line	[PMID: 14736238]
HFF	EC₅₀	39 μM Compound: 6b	In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line In vitro effective concentration required to inhibit towne strain of human cytomegalovirus (HCMV) replication in HFF cell line	[PMID: 14736238]
HFF	IC₅₀	>100 μM Compound: CPV	Antiviral activity against HSV-1 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining Antiviral activity against HSV-1 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining	[PMID: 22607883]
HFF	IC₅₀	>100 μM Compound: CPV	Antiviral activity against HSV-2 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining Antiviral activity against HSV-2 infected in human HFF cells assessed as reduction in cytopathic effect after 3 days by crystal violet staining	[PMID: 22607883]
HFF	IC₅₀	>100 μM Compound: CPV	Antiviral activity against VZV infected in human HFF cells assessed as reduction in cytopathic effect after 7 days by crystal violet staining Antiviral activity against VZV infected in human HFF cells assessed as reduction in cytopathic effect after 7 days by crystal violet staining	[PMID: 22607883]
HFF	IC₅₀	1.4 μM Compound: CPV	Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay Antiviral activity against HCMV infected in human HFF cells assessed as reduction in cytopathic effect after 8 days by plaque reduction assay	[PMID: 22607883]
MEF	CC₅₀	>380 μM Compound: 6b	In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line In vitro cytotoxic concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line	[PMID: 14736238]
MEF	EC₅₀	42 μM Compound: 6b	In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line In vitro effective concentration required to inhibit murine cytomegalovirus (MCMV) replication in MEF cell line	[PMID: 14736238]
MOLT-3	CC₅₀	>20 μM Compound: CPV	Cytotoxicity against human MOLT3 cells after 7 days by Cell-Titer Glo assay Cytotoxicity against human MOLT3 cells after 7 days by Cell-Titer Glo assay	[PMID: 22607883]
MOLT-3	IC₅₀	8 μM Compound: CPV	Antiviral activity against HHV-6B infected in human Molt3 cells assessed as reduction in viral DNA after 7 days by hybridization assay Antiviral activity against HHV-6B infected in human Molt3 cells assessed as reduction in viral DNA after 7 days by hybridization assay	[PMID: 22607883]
WI-38	CC₅₀	>100 μM Compound: Cyclopropavir	Cytotoxicity against human WI38 cells by neutral red assay Cytotoxicity against human WI38 cells by neutral red assay	[PMID: 18285481]
WI-38	EC₅₀	>100 μM Compound: Cyclopropavir	Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis Antimicrobial activity against BK polyomavirus ATCC VR837 infected in human WI38 cells assessed as reduction in viral titer after 7 days by PCR analysis	[PMID: 18285481]

体外実験

Cyclopropavir exhibits antiviral activity against HCMV in human foreskin fibroblasts (HFFs) and mouse embryo fibroblasts (MEFs)^[1].
Cyclopropavir (15 µM) inhibits UL97 kinase activity in COS7 cells transfected with UL97 and pp65-GFP fusion protein, as shown by increased formation of nuclear aggresomes^[2].
Cyclopropavir (2.5 µM; 5 days) achieves a shorter half-life compared to Ganciclovir (HY-13637) in HCMV-infected human foreskin fibroblasts (HFFs)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Cyclopropavir (1-10 mg/kg; p.o.; 5-28 days) reduces mortality and viral titers in BALB/c mice and SCID mice infected with MCMV^[4].
Cyclopropavir (10-30 mg/kg; p.o.) prevents mortality, mitigates liver/lung pathology, and reduces viral replication in immunosuppressed Syrian hamsters infected intravenously or intranasally with HAdV6^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 632325-71-4
性状 Solid
分子量 263.26
分子式 C₁₁H₁₃N₅O₃
Color White to off-white
SMILES

OCC(/C1=C/N2C3=C(C(N=C(N)N3)=O)N=C2)(C1)CO
別名

Filociclovir; ZSM-I-62; MBX-400
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 33.33 mg/mL (126.60 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7985 mL

18.9926 mL

37.9853 mL

5 mM

0.7597 mL

3.7985 mL

7.5971 mL

10 mM

0.3799 mL

1.8993 mL

3.7985 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (273 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Kern ER, et al. In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. Antimicrob Agents Chemother. 2005 Mar;49(3):1039-45. [Content Brief]

[2]. James SH, et al. Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother. 2011 Oct;55(10):4682-91. [Content Brief]

[3]. Gentry BG, et al. Metabolism of cyclopropavir and ganciclovir in human cytomegalovirus-infected cells. Antimicrob Agents Chemother. 2014;58(4):2329-33. [Content Brief]

[4]. Kern ER, et al. Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother. 2004 Dec;48(12):4745-53. [Content Brief]

[5]. Toth K, et al. Filociclovir Is a Potent In Vitro and In Vivo Inhibitor of Human Adenoviruses. Antimicrob Agents Chemother. 2020 Oct 20;64(11):e01299-20. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.7985 mL	18.9926 mL	37.9853 mL	94.9632 mL
	5 mM	0.7597 mL	3.7985 mL	7.5971 mL	18.9926 mL
	10 mM	0.3799 mL	1.8993 mL	3.7985 mL	9.4963 mL
	15 mM	0.2532 mL	1.2662 mL	2.5324 mL	6.3309 mL
	20 mM	0.1899 mL	0.9496 mL	1.8993 mL	4.7482 mL
	25 mM	0.1519 mL	0.7597 mL	1.5194 mL	3.7985 mL
	30 mM	0.1266 mL	0.6331 mL	1.2662 mL	3.1654 mL
	40 mM	0.0950 mL	0.4748 mL	0.9496 mL	2.3741 mL
	50 mM	0.0760 mL	0.3799 mL	0.7597 mL	1.8993 mL
	60 mM	0.0633 mL	0.3165 mL	0.6331 mL	1.5827 mL
	80 mM	0.0475 mL	0.2374 mL	0.4748 mL	1.1870 mL
	100 mM	0.0380 mL	0.1899 mL	0.3799 mL	0.9496 mL

Keywords

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Cyclopropavir

MCE Bioactive Compound Library

Clinical Compound Library Plus

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Cyclopropavir

MCE Bioactive Compound Library

Clinical Compound Library Plus

生物活性

化学情報

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Cyclopropavir 関連分類

HY-16721 関連分類